University of Cape Coast Institutional Repository

Nucleic Acid Amplification Testing Detects HIV Transmission Risk in Serologically- Tested Blood Donor Units

Show simple item record

dc.contributor.author Dadzie, Isaac
dc.contributor.author Muniru, Shemau
dc.contributor.author Adu, Patrick
dc.contributor.author Cudjoe, Obed
dc.date.accessioned 2023-10-23T14:56:55Z
dc.date.available 2023-10-23T14:56:55Z
dc.date.issued 2018
dc.identifier.uri http://hdl.handle.net/123456789/9873
dc.description.abstract ntroduction: Blood transfusion is an essential life-saving intervention in the healthcare delivery. Mandatory screening of donor units helps prevent transfusion-transmissible infections, such as Human Immunodeficiency Virus (HIV). Aim: The purpose of this study was to use Nucleic Acid- Amplification Testing (NAAT) to screen for the presence of HIV-1 in blood-banked samples labelled as “safe for transfusion” per serological testing algorithm. Materials and Methods: This hospital-based cross-sectional diagnostic study was conducted in May 2016 on serologically tested donor blood units in the Koforidua Regional Hospital blood bank. One hundred (100) donor samples were analysed using the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Qual Test for the detection of HIV-1 RNA and proviral DNA. Results: Of the 100 donor samples that tested sero-negative for HIV-1 and 2 using the antibody screening kit, four (4) samples (4%) were reactive by NAAT. Blood donors who came for donation were only males and majority (90%) were between the ages of 17-27 years. Additionally, all the NAAT HIV-1 positive samples were from participants in the 17-27 year group. Conclusion: NAAT demonstrated that a significant number of HIV-infected individuals are misdiagnosed at Ghanaian points- of-care. This finding has necessitated the need for inclusion of NAAT in donor blood screening in areas prevalent for HIV-1 in Ghana, considering the risk involved in using the licensed antibody test provided by the health authorities. In cases where NAAT screening may not be feasible, newer tests that have greater sensitivity compared to the FDA-licensed 3rd generation EIA which only detects HIV antibodies can be adopted. en_US
dc.language.iso en en_US
dc.publisher Journal of Clinical and Diagnostic Research en_US
dc.subject Blood safety, en_US
dc.subject HIV diagnosis, en_US
dc.subject Transfusion transmissible infections en_US
dc.title Nucleic Acid Amplification Testing Detects HIV Transmission Risk in Serologically- Tested Blood Donor Units en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search UCC IR


Advanced Search

Browse

My Account